Join
Live feed
·
INSIDERFilingvia Quantisnow
Genelux Corporation logo

VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
GNLX· Genelux Corporation
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GNLX (Genelux Corporation) and more on Quantisnow.